The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
January 10th 2025
Respiratory patterns and submental surface electromyography may be a reliable indicator of dysphagia among patients with myasthenia gravis.
MRD Continues to Reliably Predict Disease Progression in CRC
January 24th 2022In this poster presented at the 2022 ASCO Gastrointestinal Cancers Symposium, minimal residual disease (MRD) status as detected by postsurgery plasma cell-free DNA continued its strong track record of being a reliable predictor of disease progression in colorectal cancer (CRC).
Read More
Dr David R. Stukus on Eosinophilic Esophagitis Guidelines and the Pattern of Disease
January 24th 2022David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses guidelines for eosinophilic esophagitis, as well as some disease patterns that may occur.
Watch
Genomic Profiling Uncovers Mutations More Enriched in Early-Onset Colorectal Cancer
January 24th 2022Findings presented at the 2022 ASCO Gastrointestinal Cancers Symposium showed no significant differences in tissue and plasma genomic profiles of patients with early-onset and late-onset colorectal cancer, but a greater enrichment of the BRCA1 and PTEN mutations were noted in the tissue of those with early-onset disease.
Read More
Large, Retrospective Study Offers Insight Into AGEP Disease Course, Complications
January 22nd 2022Among the most notable findings were that acute generalized exanthematous pustulosis is typically triggered by antimicrobial agents and may be associated with complications of the liver or kidney for some patients.
Read More
Common Mutations in Chinese Patients With NSCLC Linked With Treatment Outcomes, Disease Severity
January 20th 2022The frequency of several mutations that inhibit response to tyrosine kinase inhibitors and tend to lead to increased disease severity was elevated in Chinese patients with non-small cell lung cancer.
Read More
Model Could Help Screen NSCLC Patients Likely to Benefit From Anti–PD-L1 Immunotherapy
January 19th 2022A model developed by researchers in China could help identify patients with non–small cell lung cancer (NSCLC) most likely to benefit from anti– programmed death-ligand 1 (PD-L1) immunotherapy.
Read More
Polypharmacy Linked With Rehospitalization, Death Among Patients With HF
January 19th 2022An analysis conducted in Japan among patients with acute decompensated heart failure (HF) revealed excessive polypharmacy at hospital discharge is associated with an increased risk of mortality after 1 year.
Read More
Study Highlights Health, Economic Benefits of RSV Vaccine for Older Adults
January 19th 2022With no existing respiratory syncytial virus (RSV) vaccine yet, researchers found that a vaccine comparable with the influenza vaccine could prevent tens of thousands of hospitalizations and deaths per year.
Read More
Phase 3 Data for Pembrolizumab in Hepatocellular Carcinoma Show Significant Improvements in OS, PFS
January 18th 2022Merck had previously received accelerated approval for pembrolizumab for patients with advanced hepatocellular carcinoma (HCC); an FDA panel left the approval in place while waiting on results from KEYNOTE-394.
Read More
CYNK-101 Receives Fast Track Designation for HER2-Positive Gastric/GEJ Cancers
January 18th 2022Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.
Read More
Understanding Real-World Trends in MRD Testing as Part of MM Management
January 18th 2022An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.
Read More